Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lonza Appoints Richard Ridinger as New CEO

Published: Thursday, April 05, 2012
Last Updated: Thursday, April 05, 2012
Bookmark and Share
Board of Directors elects Mr. Ridinger at a meeting on 2 April 2012.

At a meeting on 2 April 2012, the Board of Directors of Lonza elected Mr. Richard Ridinger as the new CEO of Lonza.

Mr. Ridinger will become CEO of Lonza effective 1 May. Rolf Soiron was acting CEO ad interim, since the end of January.

Richard Ridinger is 53 years old, a German national, and has extensive industrial leadership experience. “Richard Ridinger could be a person who grew up with Lonza”, said Rolf Soiron.

Soiron continues, “He is a chemical engineer who knows our industries, customers and products. With Richard Ridinger, we were not only able to attract a man of action and team player, but also a winning personality.”

Richard Ridinger has held numerous leadership functions at Henkel for 14 years and Cognis for 11 years.

Most recently, Mr. Ridinger was responsible for Care Chemicals, the largest sector at Cognis with approximately 3,000 employees.

During his tenure, sales increased by 60% to €1.75 billion over six years, as he successfully repositioned the business in the market.

Mr. Ridinger’s experience spans process development, production management, product- and marketing management of different product areas, leading global business units and finally the co-responsibility for leading a worldwide group of the specialty chemicals.

In working together with the private equity owners of Cognis, Richard Ridinger has proven his ability to achieve business excellence as well as to fulfill strategic and economical goals.

Following the takeover of Cognis by BASF at end of 2010, Richard Ridinger supported the integration of the company.

As CEO of Lonza, Mr. Ridinger has been mandated with strengthening Lonza’s market position in relevant markets, strengthening competitive capabilities, and productivity improvement in critical areas.

Productivity improvement includes project “Visp Challenge”, which is expected to contribute more than CHF 100 million over three years, and it also includes a review of group-wide structures.

The goal of these measures is a stepwise improvement of growth and return on capital.

At the 2 April meeting, the Board of Directors also appointed Mr. Marc Funk, Group General Counsel and Board Secretary, to become a member of the Management Committee.

Marc Funk joined Lonza in January 2009; prior he was associate general counsel at Merck Serono.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lonza Acquires Viral Vaccine and Vector Manufacturer Vivante GMP Solutions
Lonza expands its custom service platform to viral vaccines and gene therapy vectors.
Tuesday, August 31, 2010
Elusys Therapeutics and Lonza Enter Into Manufacturing Agreement
Lonza provides process development services and manufacturing capacity for this product using Lonza's GS Gene Expression System™.
Wednesday, June 17, 2009
Lonza Initiates Large Scale Production Capacity and Technology Platform for Antibody Drug Conjugates
Lonza plans to start large scale production of emerging product class Antibody Drug Conjugates to be utilized primarily in the treatment of cancer.
Friday, May 18, 2007
Scientific News
Pharmacy on Demand
New, portable system can be configured to produce different drugs.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Countless New, Cleaner Uses of Methane
Chemists have demonstrated the potential to use methane as a versatile chemical building block with which to make more complex molecules.
New Way to Control Chemical Reactions
Scientists have harnessed static electricity to control chemical reactions for the first time, in a breakthrough that could bring cleaner industry and cheaper nanotechnology.
Tiny 'Flasks' Speed Up Chemical Reactions
Self-assembling nanosphere clusters may improve everything from drug synthesis to drug delivery.
The Manufacturing Challenges of Nanotechnology
Head of NanoManufacturing at the Department of Engineering’s Institute for Manufacturing (IfM) Dr Michaël de Volder explains why manufacturing carbon nanotubes is so difficult – and so important.
New Material Lays Waste to Mercury Pollution
A brand new, dirt cheap, non-toxic polymer that literally sucks mercury out of water and soil is set to become a game changer in the battle against one of the world’s most reviled pollutants.
Shocking New Way to Get the Salt Out
MIT team invents efficient shockwave-based process for desalination of water.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
2015 ACS GCI Pharmaceutical Roundtable Research Grant
Request for proposals: Greener Continuous Chemistry & Engineering Technology.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!